Annovis Bio, Inc. (FRA:07X)

Germany flag Germany · Delayed Price · Currency is EUR
4.610
+0.390 (9.24%)
At close: Nov 28, 2025
-24.05%
Market Cap102.82M
Revenue (ttm)n/a
Net Income (ttm)-21.21M
Shares Outn/a
EPS (ttm)-1.23
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume10,700
Average Volume2,673
Open4.225
Previous Close4.220
Day's Range4.225 - 4.610
52-Week Range1.050 - 6.860
Betan/a
RSI66.64
Earnings DateNov 20, 2025

About Annovis Bio

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company’s lead product candidate is Buntanetap, which is in phase 2/3 to treat alzheimer’s disease, as well as in phase 3 to treat parkinson’s disease; and is in phase 2 clinical trial to treat lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial to treat later stages of alzhei... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2008
Employees 15
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol 07X
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements

News

There is no news available yet.